TMCx孵化器展示21家医疗创业公司-Insight Rx(9/21)

TMCx孵化器展示21家医疗创业公司-Insight Rx(9/21)


位置:加州旧金山

公司成立于2015年,首席执行官Sirj Goswami CEO是创始人之一。公司开发和运营云端平台,推出了在线平台InsightRX,使用定量药理学和机器学习原理来提高患者的护理水平。

该平台能通过对患者身上超时采集的药物浓度和生物标志物数据,来指导治疗决策,并且平台还能在较大的患者群体以及罕见病患者群体中收集数据,利用经过临床证实的药代动力学模型、生理学、药物基因组学、药物浓度和生物标志物,来对用药剂量进行优化。

Medical treatments are typically designed for the “average patient”. This “one-size-fits-all” approach often results in treatments being successful for some patients but not for others. The emergence of precision medicine aims to change this, by taking into account individual differences in people’s underlying biological characteristics. Precision medicine gives healthcare practitioners better tools to improve understandings of complex mechanisms underlying a patient’s health or disease, and to better predict which treatments will be most effective.

The technology underlying the InsightRX platform incorporates the principles of quantitative pharmacology and machine learning to provide an individualized understanding of a patient’s response to treatment. Quantitative pharmacology describes in mathematical and statistical language the relationship(s) between disease, drug action, and individual variability, which enables patient specific quantitative decision-making. The InsightRX platform delivers this technology in the form of easy to use clinical decision support tools at the point of care to help guide treatment decision-making.

The InsightRX platform guides treatment decisions at both the individual level and the population level. At the individual level, drug concentration and biomarker data are collected over-time to learn about the patient response and optimize treatment. At the population level, as more data is collected in larger patient populations, or in infrequently encountered patient populations, our pharmacological models and clinical algorithms that guide treatment recommendations will learn and will become more precise.